Author: claimsbot

1. A method for the production of a plastic part (5) that has an opaque body and a front surface with at least one translucent area delineated from an opaque area, comprising the steps of
a) injection molding a blank (1) from an opaque plastic component with a recessed volume (2) in the blank corresponding in shape and position to the translucent area, the recessed volume (2) extending from an opening in a face of said blank and inwardly of said blank; and
b) over-molding at least said face of the blank (1) with a layer of a coloured plastic component in a manner to over-span the opening in the face of the blank (1), the layer being sufficiently thin to be translucent.
2. The method according to claim 1, wherein both plastic components are injected consecutively in the same mold.
3. The method according to claim 1, wherein the opaque plastic component is injected in a first mold and the coloured plastic component is injected in a second mold.
4. The method according to claim 1, wherein the recessed volume (2) extends completely through the blank (1).
5. The method according to claim 1, wherein the recessed volume (2) extends perpendicularly to said face of the blank (1).

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula II
wherein:
Q is pyrazole or imidazole;
R1, R2, and R3 are independently hydrogen, alkyl, substituted alkyl or halogen;
R4 is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, halogen, cycloalkyl, or substituted cycloalkyl;
R5 is hydrogen, alkyl, substituted alkyl, alkylidene, substituted alkylidene, haloalkyl, arylalkyl, alkanoyl, substituted alkanoyl, aminoalkyl, substituted aminoalkyl, hydroxyalkyl, amide, substituted amide, carbamate, substituted carbamate, ureido, sulfonamide, substituted sulfonamide, alkylsulfone, heterocycloalkyl, substituted heterocycloalkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkylalkyl, thioalkyl, alkylsulfonyl, alkylsulfinyl, carboxy, alkoxycarbonyl, carbamoyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, aryloxyalkyl, aryloxyaryl, heterocyclyl substituted heterocyclyl, alkylcarbonyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl, substituted heteroalkynyl, arylsulfonyl, arylalkylsulfonyl, alkylsulfonyl, or alkylaminocarbonyl, \u2014COalkyl, \u2014CO substituted alkyl; \u2014COaryl, \u2014CO substituted aryl, \u2014CO heteroaryl, \u2014CO substituted heteroaryl, \u2014CO heterocyclyl, \u2014CO substituted heterocyclyl, \u2014CONHalkyl, \u2014CONH substituted alkyl; \u2014CONH aryl, \u2014CONH substituted aryl, \u2014CONH heteroaryl, \u2014CONH substituted heteroaryl, \u2014CONH heterocyclyl, \u2014CONH substituted heterocyclyl, \u2014SO2 alkyl, \u2014SO2 substituted alkyl; \u2014SO2 aryl, \u2014SO2 substituted aryl, \u2014SO2 heteroaryl, \u2014SO2 substituted heteroaryl, \u2014SO2 heterocyclyl or \u2014SO2 substituted heterocyclyl;
R6 is hydrogen, halogen, cyano, hydroxy, oxo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl or substituted heteroalkynyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
2. A compound of formula III
wherein:
Q is pyrazole or imidazole;
R1, R2, and R3 are independently hydrogen, alkyl, substituted alkyl or halogen;
R4 is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, halogen, cycloalkyl, or substituted cycloalkyl;
R5 is hydrogen, alkyl, substituted alkyl, alkylidene, substituted alkylidene, hydroxy, alkoxy, halogen, haloalkyl, haloalkoxy, oxo, aryloxy, arylalkyl, arylalkyloxy, alkanoyl, substituted alkanoyl, alkanoyloxy, amino, aminoalkyl, substituted aminoalkyl, alkylamino, substituted alkylamino, hydroxyalkyl, disubstituted amino, amide, substituted amide, carbamate, substituted carbamate, ureido, cyano, sulfonamide, substituted sulfonamide, alkylsulfone, heterocycloalkyl, substituted heterocycloalkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkylalkyl, cycloalkylalkoxy, nitro, thio, thioalkyl, alkylthio, alkylsulfonyl, alkylsulfinyl, carboxy, alkoxycarbonyl, alkylcarbonyloxy, carbamoyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heteroaryloxy, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, heterocyclyl substituted heterocyclyl, alkylcarbonyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl, substituted heteroalkynyl, arylamino, arylalkylamino, alkanoylamino, aroylamino, arylalkanoylamino, arylthio, arylalkylthio, arylsulfonyl, arylalkylsulfonyl, alkylsulfonyl, arylcarbonylamino, or alkylaminocarbonyl, \u2014COalkyl, \u2014CO substituted alkyl, \u2014COaryl, \u2014CO substituted aryl, \u2014CO heteroaryl, \u2014CO substituted heteroaryl, \u2014CO heterocyclyl, \u2014CO substituted heterocyclyl, \u2014CONHalkyl, \u2014CONH substituted alkyl; \u2014CONH aryl, \u2014CONH substituted aryl, \u2014CONH heteroaryl, \u2014CONH substituted heteroaryl, \u2014CONH heterocyclyl, \u2014CONH substituted heterocyclyl, \u2014SO2 alkyl, \u2014SO2 substituted alkyl; \u2014SO2 aryl, \u2014SO2 substituted aryl, \u2014SO2 heteroaryl, \u2014SO2 substituted heteroaryl, \u2014SO2 heterocyclyl or \u2014SO2 substituted heterocyclyl;
R6 is hydrogen, halogen, cyano, hydroxy, oxo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl or substituted heteroalkynyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
3. A compound of formula IV
wherein:
R1, R2, and R3 are independently hydrogen, alkyl, substituted alkyl or halogen;
R4 is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, halogen, cycloalkyl, or substituted cycloalkyl;
R5 is hydrogen, alkyl, substituted alkyl, alkylidene, substituted alkylidene, haloalkyl, arylalkyl, alkanoyl, substituted alkanoyl, aminoalkyl, substituted aminoalkyl, hydroxyalkyl, amide, substituted amide, carbamate, substituted carbamate, ureido, sulfonamide, substituted sulfonamide, alkylsulfone, heterocycloalkyl, substituted heterocycloalkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkylalkyl, thioalkyl, alkylsulfonyl, alkylsulfinyl, carboxy, alkoxycarbonyl, carbamoyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, aryloxyalkyl, aryloxyaryl, heterocyclyl substituted heterocyclyl, alkylcarbonyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl, substituted heteroalkynyl, arylsulfonyl, arylalkylsulfonyl, alkylsulfonyl, or alkylaminocarbonyl,
\u2014COalkyl, \u2014CO substituted alkyl; \u2014COaryl, \u2014CO substituted aryl, \u2014CO heteroaryl, \u2014CO substituted heteroaryl, \u2014CO heterocyclyl, \u2014CO substituted heterocyclyl, \u2014CONHalkyl, \u2014CONH substituted alkyl; \u2014CONH aryl, \u2014CONH substituted aryl, \u2014CONH heteroaryl, \u2014CONH substituted heteroaryl, \u2014CONH heterocyclyl, \u2014CONH substituted heterocyclyl, \u2014SO2 alkyl, \u2014SO2 substituted alkyl; \u2014SO2 aryl, \u2014SO2 substituted aryl, \u2014SO2 heteroaryl, \u2014SO2 substituted heteroaryl, \u2014SO2 heterocyclyl or \u2014SO2 substituted heterocyclyl;
R6 is hydrogen, halogen, cyano, hydroxy, oxo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl or substituted heteroalkynyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
4. A compound of formula V
wherein:
R1, R2, and R3 are independently hydrogen, alkyl, substituted alkyl, or halogen;
R4 is hydrogen, alkyl, substituted alkyl, hydroxy, alkoxy, halogen, cycloalkyl, or substituted cycloalkyl;
R5 is hydrogen, alkyl, substituted alkyl, alkylidene, substituted alkylidene, hydroxy, alkoxy, halogen, haloalkyl, haloalkoxy, oxo, aryloxy, arylalkyl, arylalkyloxy, alkanoyl, substituted alkanoyl, alkanoyloxy, amino, aminoalkyl, substituted aminoalkyl, alkylamino, substituted alkylamino, hydroxyalkyl, disubstituted amino, amide, substituted amide, carbamate, substituted carbamate, ureido, cyano, sulfonamide, substituted sulfonamide, alkylsulfone, heterocycloalkyl, substituted heterocycloalkyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, cycloalkylalkyl, cycloalkylalkoxy, nitro, thio, thioalkyl, alkylthio, alkylsulfonyl, alkylsulfinyl, carboxy, alkoxycarbonyl, alkylcarbonyloxy, carbamoyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heteroaryloxy, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, heterocyclyl substituted heterocyclyl, alkylcarbonyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl, substituted heteroalkynyl, arylamino, arylalkylamino, alkanoylamino, aroylamino, arylalkanoylamino, arylthio, arylalkylthio, arylsulfonyl, arylalkylsulfonyl, alkylsulfonyl, arylcarbonylamino, or alkylaminocarbonyl, \u2014COalkyl, \u2014CO substituted alkyl, \u2014COaryl, \u2014CO substituted aryl, \u2014CO heteroaryl, \u2014CO substituted heteroaryl, \u2014CO heterocyclyl, \u2014CO substituted heterocyclyl, \u2014CONHalkyl, \u2014CONH substituted alkyl, \u2014CONH aryl, \u2014CONH substituted aryl, \u2014CONH heteroaryl, \u2014CONH substituted heteroaryl, \u2014CONH heterocyclyl, \u2014CONH substituted heterocyclyl, \u2014SO2 alkyl, \u2014SO2 substituted alkyl; \u2014SO2 aryl, \u2014SO2 substituted aryl, \u2014SO2 heteroaryl, \u2014SO2 substituted heteroaryl, \u2014SO2 heterocyclyl or \u2014SO2 substituted heterocyclyl;
R6 is hydrogen, halogen, cyano, hydroxy, oxo, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, substituted heteroalkenyl, heteroalkynyl or substituted heteroalkynyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof.
6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 2 or a pharmaceutically acceptable salt or stereoisomer thereof.
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 3 or a pharmaceutically acceptable salt or stereoisomer thereof.
8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of claim 4 or a pharmaceutically acceptable salt or stereoisomer thereof.
9. A method for the treatment of breast cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a stereoisomer or pharmaceutically acceptable salt thereof.

1. An injection molded article formed by a process comprising:
providing a polyolefin comprising one or more propylene heterophasic copolymers, the polyolefin having an ethylene content of at least 10 wt. % based on the total weight of the polyolefin;
contacting the polyolefin with a polylactic acid and a reactive modifier to form a compatiblized polymeric blend, wherein the reactive modifier is produced by contacting a polypropylene, a multifunctional acrylate comonomer, and an initiator under conditions suitable for the formation of a glycidyl methacrylate grafted polypropylene (PP-g-GMA) having a grafting yield in a range from 1 wt. % to 15 wt. %; and
injection molding the compatibilized polymeric blend into an article.
2. The injection molded article of claim 1, wherein the one or more propylene heterophasic copolymers has an average ethylene content in a range from 11.5 wt. % to 18 wt. % based on the total weight of the copolymers.
3. The injection molded article of claim 1, wherein the polyolefin further comprises an elastomer comprising ethylene.
4. The injection molded article of claim 1, wherein the polyolefin further comprises polyethylene.
5. The injection molded article of claim 1, wherein the polyolefin has an ethylene content in a range from 11.5 wt. % to 18 wt. % based on the total weight of the polyolefin.
6. The injection molded article of claim 1, wherein the grafting yield of glycidyl methacrylate (GMA) is at least 1.5 wt. %.
7. The injection molded article of claim 1, wherein the grafting yield of glycidyl methacrylate (GMA) is in a range from about 2 wt. % to about 15 wt. %.
8. The injection molded article of claim 1, wherein the article exhibits a flexural modulus in a range from 150 kpsi to 500 kpsi.
9. The injection molded article of claim 1, wherein the article exhibits a tensile modulus in a range from 170 kpsi to 400 kpsi.
10. The injection molded article of claim 1, wherein the article exhibits a tensile yield strength in a range from 2800 psi to 4500 psi.
11. The injection molded article of claim 1, wherein the article exhibits a notched Izod impact strength in a range from 2.1 ft-lbin to 15 ft-lbin.
12. The injection molded article of claim 1, wherein the article exhibits a flexural modulus of at least 150 kpsi and a notched Izod impact strength in a range from 2.1 ft-lbin to 15 ft-lbin.
13. The injection molded article of claim 1, wherein the article exhibits a flexural modulus of at least 150 kpsi and a notched Izod impact strength in a range from 3 ft-lbin to 15 ft-lbin.
14. The injection molded article of claim 1, wherein the article is an automotive part.
15. A method of forming an injection molded article comprising:
providing a polyolefin comprising one or more propylene heterophasic copolymers, the polyolefin having an ethylene content of at least 10 wt. % based on the total weight of the polyolefin;
melt blending the polyolefin with a polylactic acid and a reactive modifier to form a compatiblized polymeric blend, wherein the reactive modifier is produced by contacting a polypropylene, a multifunctional acrylate comonomer, and an initiator under conditions suitable for the formation of a glycidyl methacrylate grafted polypropylene (PP-g-GMA) having a grafting yield in a range from 1 wt. % to 15 wt. %; and
injection molding the compatibilized polymeric blend into an article.
16. The method of claim 15, wherein the one or more propylene heterophasic copolymers has an average ethylene content in a range from 11.5 wt. % to 18 wt. % based on the total weight of the copolymers.
17. The method of claim 15, wherein the polyolefin further comprises an elastomer comprising ethylene.
18. The method of claim 15, wherein the polyolefin further comprises polyethylene.
19. The method of claim 15, wherein the polyolefin has an ethylene content in a range from 11.5 wt. % to 18 wt. % based on the total weight of the polyolefin.
20. The method of claim 15, wherein the melt blending step includes melt blending the polyolefin with the polylactic acid, an inorganic filler, and the reactive modifier to form the compatiblized polymeric blend.
21. The method of claim 15, wherein the polylactic acid has a concentration of from about 3 wt. % to about 20 wt. % based on the weight of the compatibilized polymeric blend.
22. The method of claim 15, wherein the reactive modifier has a concentration in a range from about 1 wt. % to about 15 wt. % based on the weight of the compatibilized polymeric blend.
23. The method of claim 15, wherein the multifunctional acrylate comonomer is selected from polyethylene glycol diacrylate, alkoxylated hexanediol diacrylate, trimethylolpropane triacrylate, propoxylated neopentyl glycol diacrylate, ethoxylated trimethylolpropane triacrylate, diethylene glycol diacrylate, tris(2-hydroxyethyl)isocyanurate triacrylate, and combinations thereof.
24. The method of claim 15, wherein the grafting yield of glycidyl methacrylate (GMA) is at least 1.5 wt. %.
25. The method of claim 15, wherein the grafting yield of glycidyl methacrylate (GMA) is in a range from about 2 wt. % to about 15 wt. %.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for modifying a VTBI at a medical device operably connected to a medication management unit, the method comprising:
delivering an infusion fluid based an a current VTBI;
receiving a request to modify the current VTBI at the medical device;
displaying a VTBI programming screen at a display screen of the medical device;
receiving an updated VTBI at the programming screen; and
receiving a confirmation to modify the current VTBI with the updated VTBI.
2. A medication management system for modifying a VTBI delivery function of a medical device operably connected to the medication management system, the system comprising:
a medication management unit having a processing unit and a storage medium coupled to the processing unit, the storage medium containing programming code executed by the processing unit; and
a medical device in electronic communication with the medication management unit, having a processor and a memory coupled to the processor, the memory containing programming code to:
deliver an infusion fluid based an a current VTBI;
receive a request to modify the current VTBI at the medical device;
display a VTBI programming screen at a display screen of the medical device;
receive an updated VTBI at the programming screen; and
receive a confirmation to modify the current VTBI with the updated VTBI.
3. (canceled)
4. A medical device operably connected to a medication management unit, the device comprising:
a display screen configured to display a far view delivery screen;
at least one quick titration button located on the far view delivery screen wherein the at least one quick titration button is configured to navigate directly to a data entry screen associated with the at least one quick titration button.
5. A medical device operably connected to a medication management unit, the device comprising:
a processor and a memory coupled to the processor, the memory containing programming code to:
display a far view delivery screen;
display at least one quick titration button on the far view delivery screen;
navigate directly to a data entry screen associated with the at least one quick titration button in response to receiving a user input.